Literature DB >> 7436504

Liver disease complicating severe haemophilia in childhood.

K M McGrath, J S Lilleyman, D R Triger, J C Underwood.   

Abstract

Liver biopsies were performed in 5 boys aged between 2 and 9 years with severe classical haemophilia who had persistently abnormal liver function tests. Abnormal histology was present in all; 4 had chronic persistent hepatitis and the fifth chronic aggressive hepatitis with early cirrhosis. Evidence of previous hepatitis B infection was present in one patient, 3 had antibodies to hepatitis, A, and 2 had subnormal levels of alpha-1-antitrypsin. Haemobilia occurred as a late complication of biopsy in one. The significance of these findings in young boys is discussed, as is the role of exposure to factor VIII containing blood products. It is concluded that cryoprecipitate should be used in preference to large pool factor VIII concentrates in children with haemophilia.

Entities:  

Mesh:

Year:  1980        PMID: 7436504      PMCID: PMC1626797          DOI: 10.1136/adc.55.7.537

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  9 in total

1.  Asymptomatic liver disease in haemophiliacs.

Authors:  P M Mannucci; A Capitanio; E Del Ninno; M Colombo; F Pareti; Z M Ruggeri
Journal:  J Clin Pathol       Date:  1975-08       Impact factor: 3.411

2.  Hepatocellular carcinoma and intermediate alpha1-antitrypsin deficiency (MZ phenotype).

Authors:  J Lieberman; R M Silton; C M Agliozzo; J McMahon
Journal:  Am J Clin Pathol       Date:  1975-09       Impact factor: 2.493

3.  Asymptomatic structural liver disease in hemophilia.

Authors:  J A Spero; J H Lewis; D H Van Theil; U Hasiba; B S Rabin
Journal:  N Engl J Med       Date:  1978-06-22       Impact factor: 91.245

4.  Percutaneous liver biopsy and chronic liver disease in haemophiliacs.

Authors:  F E Preston; D R Triger; J C Underwood; G Bardhan; V E Mitchell; R M Stewart; E K Blackburn
Journal:  Lancet       Date:  1978-09-16       Impact factor: 79.321

5.  Cirrhosis and heterozygous alpha1-antitrypsin deficiency in a 4-year-old girl.

Authors:  M Cruz; J A Molina; D Pedrola; F Muñoz-López
Journal:  Helv Paediatr Acta       Date:  1976-04

6.  Liver biopsy in hemophilia A.

Authors:  H R Lesesne; J E Morgan; P M Blatt; W P Webster; H R Roberts
Journal:  Ann Intern Med       Date:  1977-06       Impact factor: 25.391

7.  Viral exposure and abnormal liver function in haemophilia.

Authors:  B A McVerry; M G Ross; W A Knowles; J Voke
Journal:  J Clin Pathol       Date:  1979-04       Impact factor: 3.411

8.  A clinicopathological study of liver disease in haemophiliacs.

Authors:  P M Mannucci; G Ronchi; L Rota; M Colombo
Journal:  J Clin Pathol       Date:  1978-08       Impact factor: 3.411

9.  Health of the intensively treated hemophiliac, with special reference to abnormal liver chemistries and splenomegaly.

Authors:  P H Levine; B A McVerry; B Attock; K M Dormandy
Journal:  Blood       Date:  1977-07       Impact factor: 22.113

  9 in total
  5 in total

1.  HTLV-III, haemophilia and blood transfusion.

Authors:  V E Mitchell; C Martin; A J Flower
Journal:  Br Med J (Clin Res Ed)       Date:  1985-07-20

2.  Post-transfusion hepatitis.

Authors: 
Journal:  Br Med J (Clin Res Ed)       Date:  1981-07-04

3.  Cirrhosis associated with multiple transfusions in thalassaemia.

Authors:  G Jean; S Terzoli; R Mauri; L Borghetti; A Di Palma; A Piga; M Magliano; M Melevendi; M Cattaneo
Journal:  Arch Dis Child       Date:  1984-01       Impact factor: 3.791

4.  Hemobilia as the initial manifestation of cholangiocarcinoma in a hemophilia B patient.

Authors:  Anastassios-C Manolakis; Andreas-N Kapsoritakis; Antonis-D Tsikouras; Fotis-D Tsiopoulos; Athanassios-K Psychos; Spyros-P Potamianos
Journal:  World J Gastroenterol       Date:  2008-07-14       Impact factor: 5.742

5.  Coagulation factor therapy for hemophilia: relation to hepatitis B and to liver function.

Authors:  R T Card; M Dusevic; B E Lukie
Journal:  Can Med Assoc J       Date:  1982-01-01       Impact factor: 8.262

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.